The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation

International Journal of Hematology
Vilma DembitzDora Visnjic

Abstract

Arsenic trioxide (ATO) has potent clinical activity in the treatment of patients with acute promyelocytic leukemia (APL), but is much less efficacious in acute myeloid leukemia (AML) lacking t(15;17) translocation. Recent studies have indicated that the addition of mammalian target of rapamycin (mTOR) inhibitors may increase the sensitivity of malignant cells to ATO. The aim of the present study was to test for possible synergistic effects of ATO and rapamycin at therapeutically achievable doses in non-APL AML cells. In HL-60 and U937 cell lines, the inhibitory effects of low concentrations of ATO and rapamycin were synergistic and more pronounced in U937 cells. The combination of drugs increased apoptosis in HL-60 cells and increased the percentage of cells in G(0)/G(1) phase in both cell lines. In U937 cells, rapamycin alone increased the activity of mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and the addition of ATO decreased the level of phosphorylated ERK, Ser473 phosphorylated Akt and anti-apoptotic Mcl-1 protein. Primary AML cells show high sensitivity to growth-inhibitory effects of rapamycin alone or in combination with ATO. The results of the present study reveal the mechanism of ...Continue Reading

References

Nov 20, 2004·Blood·Christian RécherBernard Payrastre
Feb 22, 2005·The Journal of Pharmacology and Experimental Therapeutics·Geniece McCollumMichael J McCabe
Dec 1, 2007·The Journal of Biological Chemistry·Jessica K AltmanLeonidas C Platanias
Jul 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·John R MillsJerry Pelletier
Apr 28, 2009·Cancer Chemotherapy and Pharmacology·Jonathan T Sims, Rina Plattner
Sep 24, 2010·Leukemia & Lymphoma·Kazuto SuganumaMasakazu Nitta
Mar 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jessica K AltmanLeonidas C Platanias
Jul 11, 2012·The Journal of Cell Biology·Hugues de ThéValérie Lallemand-Breitenbach
Feb 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Akio IwanamiPaul S Mischel
May 29, 2013·Immunology·Alessia MercalliLorenzo Piemonti
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Feb 1, 2014·Nature Reviews. Drug Discovery·David A Fruman, Christian Rommel

❮ Previous
Next ❯

Citations

Jan 19, 2018·Current Medicinal Chemistry·Dora VisnjicHrvoje Lalic
Apr 23, 2021·Cancer & Metabolism·Svetlana B PaninaNatalia V Kirienko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.